IX BIOPHARMA LTD.

(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

CHANGES IN THE COMPOSITION OF THE BOARD AND BOARD COMMITTEES

The Board of Directors (the "Board") of iX Biopharma Ltd. (the "Company") wishes to announce the following changes with effect from 27 October 2021:

(1) Mr. Patrick Donald Davies be appointed as the Chairperson of the Nominating Committee and a member of Risk Management Committee; and

(2) Mr. Albert Ho Shing Tung be appointed as the Chairperson of the Risk Management Committee.

Mr. Patrick Donald Davies was appointed to the Board as an Independent Director on 2 December 2019 and serves as the Chairperson of the Remuneration Committee and a member of the Audit and Nominating Committees.

Mr. Albert Ho Shing Tung was appointed to the Board as a Non-Executive Non-Independent Director on 1 March 2013 and serves as a member of the Audit, Remuneration and Risk Management Committees.

Consequent to the abovementioned changes, with effect from 27 October 2021, the composition of the Board and Board Committees will be as follows:

Board of Directors	**Designation**
Eddy Lee Yip Hang	Executive Chairman and Chief Executive Officer
Albert Ho Shing Tung	Non-Executive Non-Independent Director
Patrick Donald Davies	Non-Executive Lead Independent Director
Low Weng Keong	Non-Executive Independent Director
Audit Committee	
Low Weng Keong	Chairperson
Albert Ho Shing Tung	Member
Patrick Donald Davies	Member
Remuneration Committee	
Patrick Donald Davies	Chairperson
Low Weng Keong	Member
Albert Ho Shing Tung	Member
Nominating Committee	
Patrick Donald Davies	Chairperson
Eddy Lee Yip Hang	Member
Low Weng Keong	Member
Risk Management Committee	
Albert Ho Shing Tung	Chairperson
Low Weng Keong	Member
Patrick Donald Davies	Member

The Company has commenced the search for a new independent director and will make an announcement when a new appointment is made.

By Order of the Board

Lee Wei Hsiung / Wang Shin Lin, Adeline
Company Secretaries

27 October 2021

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.